ATM and cancer: Recently, several papers have investigated the role of ATM mutations in cancer susceptibility and prognosis, suggesting that such mutations induce an attenuated cancer-predisposing phenotype in heterozygote carriers, that represent up to 1–2% of the general population [37], while presenting a favorable prognostic effect in CRCs bearing such heterozygous alterations [38].